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Abstract
Multiple myeloma (MM) is a B cell neoplasm characterized by bone marrow infiltration with malignant plasma cells. IGF-1
signalling has been explored as a therapeutic target in this disease. We analyzed the effect of the IKK2 inhibitor AS602868, in
combination with a monoclonal antibody targeting IGF-1 receptor (anti-IGF-1R) in human MM cell lines. We found that anti-
IGF-1R potentiated the apoptotic effect of AS602868 in LP1 and RPMI8226 MM cell lines which express high levels of IGF-1R.
Anti-IGF-1R enhanced the inhibitory effect of AS602868 on NF-kB pathway signalling and potentiated the disruption of
mitochondrial membrane potential caused by AS602868. These results support the role of IGF-1 signalling in MM and
suggest that inhibition of this pathway could sensitize MM cells to NF-kB inhibitors.
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Introduction
Multiple myeloma is characterized by unrestrained accumula-
tion of antibody-secreting plasma cells in the bone marrow,
attributed to loss of apoptotic control and cell cycle deregulation
[1,2]. Its incidence is approximately 4/100,000 persons per year,
but is predicted to increase in the future due to the expected
increase in longevity. The proliferation and the survival of MM
cell lines and fresh human cells has been shown to be related to the
activation of several pathways such as phosphatidylinositol-3
kinase (PI-3K)/Akt, Janus kinase (JAK)/signal transducer and
activator of transduction 3 (STAT3), mitogen-activated protein
kinase (MAPK)/extracellular signal-regulated kinase (ERK) and
nuclear factor kappa-B (NF-kB) [3,4,5,6,7]. Several growth factors
produced by the microenvironment induce the activation of these
pathways such as interleukin 6 (IL-6), and insulin-like growth
factor 1(IGF-1) [8,9]. In vivo and in vitro, IGF-1 decreases drug
sensitivity of MM cells, and upregulates a series of anti-apoptotic
proteins such as A1/Bfl-1, XIAP and Bcl-2 [10,11,12].
Several strategies seek to target and inhibit the IGF-1
signalisation pathway, either by blocking the IGF-1 receptor or
by inhibiting the signals downstream of this receptor [13,14,15].
Monoclonal antibodies targeting the IGF-1R constitute a very
attractive approach to block the IGF-1/IGF-1R interaction,
subsequently blocking the stimulation of several signalisation
pathways, especially PI-3K/Akt and NF-kB [16]. Inactive NF-kB
is located in the cytosol associated to different NF-kB inhibitory
proteins (IkB) [17]. Many stimuli such as growth factors, stress
and inflammatory response induce the phosphorylation of IkB
proteins, thereby activating their ubiquitination and degradation
by the 26S proteasome [18]. The IkB kinase complex (IKK) is
responsible for the phosphorylation of IkB. IKK include three
subunits, the two catalytic subunits IKK1 (IKKa) and IKK2
(IKKb), and the regulatory subunit Nemo (IKKc) [19,20,21]. The
IKK kinase complex indirectly regulates the translocation of NF-
kB to the nucleus and the transcription of growth and survival
genes. While inhibition of the NF-kB pathway has been suggested
to be a significant mechanism of proteasome inhibitors such as
bortezomib [22], another approach to inhibit this pathway consists
in the inhibition of IKK [23]. IKK inhibitors could have
anticancer effects per se or could potentiate agents interfering on
signalisation pathways upstream of NF-kB, as seems to be the case
for IGF-1R inhibitors.
AS602868 is an anilinopyrimide derivative and adenosine
triphosphatase competitor selected for its inhibitory effect on
IKK2 in vitro. AS602868 induces the apoptosis of MM, acute
myeloid leukemia and sarcoma cell lines in vitro [24,25,26]. It has
also been shown that AS602868 blocks the canonical NF-kB
pathway and the proliferation of MM cell lines [27].
Recent work from our laboratory recently identified gene
expression profiles in fresh human acute myeloid leukemia cells
exposed to AS602868 and suggests that multiple mechanisms,
including pathways other than NF-kB may be induced by this
agent [28].
In this study, we analysed the effect of the combination of the
IKK2 inhibitor AS602868 and a monoclonal antibody directed
against IGF-1R on MM cell lines. AS602868 was found to block
the activation of NF-kB, induced a dissipation of mitochondrial
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22641transmembrane potential and induced apoptosis in MM cell lines.
The combination of the anti IGF-1R antibody with AS602868
increased the cytotoxic effect in MM cell lines, suggesting that
simultaneous targeting of IGF-1 signalling and the NF-kB
pathway could be of therapeutic value in multiple myeloma.
Results
IGF-1R expression level
In a first step, we measured the expression level of IGF-1Ra by
flow cytometry in the different MM cell lines. We found that
RPMI8226 and LP1 expressed more IGF-1Ra than MM.1S and
U266 (Figure 1A). Since IGF-1 can also bind the insulin receptor
(IR) and the insulin-like growth factor 2 receptor (IGF-2R), we
analyzed the expression of IGF-1R, IGF- 2R and IR by
quantitative RT-PCR. We confirmed that LP1 and RPMI8226
expressed a higher level of IGF receptor than MM.1S and U266
(Figure 1B).
Combining the anti-IGF-1R monoclonal antibody with
the IKK2 inhibitor AS602868 increases the apoptosis of
MM cell lines
In order to study the effect of the combination of the IKK2
inhibitor AS602868 and the anti- IGF-1R monoclonal antibody
on four human MM cell lines, we incubated cells with various
concentrations of AS602868 alone or in combination with 10 mg/
mL anti-IGF-1R. While AS602868 was cytotoxic against the four
cell lines studied, the combination with anti-IGF-1R antibody
enhanced cytotoxicity significantly only in RPMI8226 and LP1
cells (Figure 2A). IC50 for AS602868 were reduced from 35 mMt o
10 mM upon addition of anti-IGF-1R in RPMI8226 cell line and
39 mMt o7mM in LP1 cell line. The combination of anti-IGF-1R
with AS602868 had not any additional effect on MM.1S and
U266 cell lines (Figure 2A) which express lower levels of IGF-1R.
Same experience is performed without serum; such as the first
experience, the effect effect of AS602868 was enhanced by anti-
IGF-1R antibody (Figure S2).
To determine if the potential effect of anti-IGF-1R was related
to the inhibition of IKK2, we studied the viability and apoptosis of
MM cell lines in presence of the selective IKK2 inhibitor, TPCA-
1. This inhibitor decreased the viability of the four cell lines.
However, the cytotoxic effect of TPCA-1 was enhanced by anti-
IGF-1R only in LP1 and RPMI8226 cells (Figure 2B).
To confirm these results, we measured the induction of apoptosis
by annexin V staining in cells exposed to 10 mM AS602868, TPCA
or/and 10 mg/mLanti-IGF-1Rantibody.Interestingly,the fourcell
lines showed an apoptotic response upon incubation for 72 hours
with 10 mM AS602868, TPCA-1 or/and 10 mg/mL anti-IGF-1R.
However, anti-IGF-1R antibody enhanced apoptosis induced by
theseagentsonlyintheinLP1andRPMI8226celllines(Figure2C).
Growth inhibition studies showed that MM.1S and U266 were
more resistant to anti-IGF-1 then LP1 and RPMI8226 (Figure S1).
The combination of anti-IGF- 1R with AS602868 or with TPCA-1
was found to increase the apoptotic fraction in RPMI8226 and LP1
cells but not in MM.1S and U266 cells (Figure 2C). To understand
how the inhibition of IKK2 and the IGF-1R antibody could
cooperate to cause cell death in myeloma cells we then chose to
focus on the two cells lines with the highest levels of IGF-1R, LP1
and RPMI8226.
Combining the anti-IGF-1R monoclonal antibody with
the IKK2 inhibitor AS602868 increases the apoptosis of
primary myeloma cells
Since anti-IGF-1R antibody enhanced the cytotoxicity effect of
the IKK2 inhibitors on MM cell lines, we evaluated the effect of
this combination on primary MM cells. We incubated primary
myeloma cells with IKK2 inhibitors or/and anti-IGF-1R antibody
for 24 h. We analyzed the effect of these signalling pathways
inhibitors on CD221+ and CD2212 plasma cells. About 30% of
primary plasma cells express IGF-1R (CD221+) (Table S3). After
24 h, anti-IGF- 1R antibody increased the apoptotic fraction from
5% to 20% in CD221+ plasma cells with no significant effect on
CD2212 plasma cells (Figure 2D). The effect of AS602868 was
more pronounced on CD221+ plasma cells then on CD2212
plasma cells. The apoptotic effect of the combination was detected
only on CD221+ plasma cells (Figure 2D). Anti-IGF-1R antibody
and AS602868 were not any cytotoxicity effect on bone marrow
non plasma cell compartment (Table S4).
Figure 1. Level expression of IGFs receptors on four MM cell lines. 1.A Level expression of IGF-1Ra by flow ctometry on RPMI8226, LP1,
MM.1S and U266. 1.B Expression of IGF-1R, IR and IGF-2R by RT-PCR on RPMI8226, LP1, MM.1S and U266.
doi:10.1371/journal.pone.0022641.g001
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progression in MM cell lines
In order to determine the effect of AS602868 and/or anti-IGF-
1R on cell cycle progression, we exposed LP1, RPMI8226,
MM.1S and U266 cells lines to 10 mM AS602868 and/or 10 mg/
mL anti-IGF-1R antibody. AS602868 alone caused a strong block
of cells in the S phase of the cell cycle in the four cell lines, whereas
anti-IGF-1R antibody blocked cells in G0–G1 phase only in the
LP1 and RPMI8226 lines. When cells were exposed to both
molecules, more than 70% of LP1 and RPMI8226 cells were
blocked in G0–G1 (Figure 3A). Of note the degree and pattern of
cell cycle blockage was quite similar in these two IGF-1R positive
lines. Cdc2 p34 is essential for the G2 to M transition. In this
study, the analysis of the expression level of cdc2 p34 showed that
this protein became undetectable after exposure to AS602868 in
the RPMI8226 cells, either alone or in combination with anti-IGF-
1R antibody (Figure 3B). We also analysed the level expression of
cyclin A. AS602868 decreased the expression of cyclin A. This
reduced content is compatible with the S phase block observed in
cells exposed to AS602868. We also analysed the expression level
of the cyclin D inhibitor, p21. As shown in Figure 3B, anti-IGF-1R
alone or in combination with AS602868 enhanced the expression
level of p21 and reduced the expression level of cyclin E which is in
keeping with the G0/G1 block observed in cells exposed to anti-
IGF-1R (Figure 3B). The expression level of the tumor supressor
P53 increased in cells incubated with anti-IGF-1R or AS602868,
as well as in cells exposed to the combination of anti-IGF-1R and
AS602868 (Figure 3B).
Effect of AS602868 and anti-IGF-1R antibody on
mitochondrial membrane potential
Apoptosis can be related to the release of pro-apoptotic proteins
from mitochondria. In order to determine the apoptotic
mechanisms triggered by AS602868 and anti-IGF-1R, we
analysed the mitochondrial potential in MM cells by DiOC6 (3).
In RPMI8226 and LP1, AS602868 induced depolarization of the
mitochondrial membrane (Figure 4A). While anti-IGF-1R in itself
did not cause depolarization of mitochondrial membrane its
combination with AS602868 caused a greater dissipation of
mitochondrial potential than did AS602868 alone. To determine
whether these alterations in mitochondrial membrane potential
were correlated with apoptotic signalling we studied the expression
Figure 2. Anti-IGF-1 antibody enhances the cytotoxic effect of IKK2 inhibitors on RPMI8226 et LP1. 2.A Anti-IGF-1R antibody enhanced
the cytotoxic effect of AS602868 on RPMI8226 and LP1 cell lines. Cells were plated in triplicate and exposed to various concentrations of AS602868 in
the presence or absence of anti-IGF-1R antibody at a fixed concentration of 10 mg/mL. Cytotoxicity was evaluated using an MTT assay. Cells exposed
to AS602868 alone were compared to controls cultured in serum alone. Cells exposed to AS602868 in the presence of Anti-IGF-1R antibody were
compared to controls cultured in presence of Anti- IGF-1R antibody alone. 2.B Anti-IGF-1R antibody enhanced the cytotoxic effect of TPCA-1 on
RPMI8226 and LP1 cell lines. Cells were plated in triplicate and exposed to various concentrations of TPCA-1 in the presence or absence of anti-IGF-1R
antibody at a fixed concentration of 10 mg/mL. Cells exposed to TPCA-1 alone were compared to controls cultured in serum alone. Cells exposed to
TPCA-1 in the presence of Anti-IGF-1R antibody were compared to controls cultured in presence of Anti-IGF-1R antibody alone. 2.C Anti-IGF-1 R
potentiated the apoptotic effect of IKK2 inhibitors AS602868 and TPCA-1 on RPMI8226 and LP1 MM cell lines. Cells were exposed for 72 h with 10 mM
AS602868 or 10 mM TPCA-1 in the presence or absence of anti-IGF-1R antibody at a fixed concentration of 10 mg/mL then analyzed by flow cytometry
after annexin V staining. Mean6 SD of three experiments ** P,0.001: * P,0.05 versus control. 2.D Effect of anti-IGF-1R antibody+AS602868 on fresh
human myeloma samples according to CD221 (IGF-1Ra) status. This combination induced more apoptosis on CD221hi plasma cells than in CD221lo
cells. Cells were incubated with 10 mM AS602868 or/and anti-IGF-1R antibody for 24 h. Apoptosis was analyzed by flow cytometry.
doi:10.1371/journal.pone.0022641.g002
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RPMI8226 and LP1 cells. We detected an increase of cytochrome
c protein content in cells incubated with AS602868. While anti
IGF-1R antibody had not effect on cytochrome c content its
association with AS602868 clearly increased the increase of
cytochrome c, in particular in LP1 cells which are those with the
highest level of expression of IGF-1R (Figure 4B).
Effect of AS602868 and anti-IGF-1R antibody on NF-kB
signalling
During activation, IKK2 is phosphorylated and induces the
phosphorylation of IkBa. In order to study the effect of the
combination anti-IGF-1R and the IKK2 inhibitor on NF-kB, we
analysed the phosphorylation status of IKK2 as well as that of its
substrate IkBa by western blot. As expected incubation of
RPMI8226 with AS602868 for 16 h decreased the phosphoryla-
tion of IKK2 with a resulting decrease in phospho-IkBa.
AS602868 also caused a decrease in p65 but no change in
phospho-p65. Conversely anti-IGF-1R antibody decreased the
phosphorylation of both IkBa and p65, suggesting that blockage of
IGF-1 signalling has a profound inhibitory effect on NF-kB
signalling (Figure 5A). Remarkably the reduction of phospho-IkBa
was maximal when anti-IGF-1R antibody was combined to
AS602868. These results suggest that inhibition of IGF-1
signalling potentiates the repression of NF-kB by an IKK inhibitor
such as AS602868.
The ability of the combination of anti-IGF-1R and an IKK2
inhibitor to interfere with NF-kB activation was also analyzed by
RT-PCR. Generally, the activation of NF-kB is accompanied with
an increased mRNA content of various molecules such as IL-6 and
Inter-Cellular Adhesion Molecule 1 (ICAM-1). In RPMI cell lines,
we observed that anti-IGF-1R does not have a significant effect on
IKB, IGF-1, IL-6 and ICAM-1 (Figure 5B). While the IKK2
inhibitor decreased the expression level of IkB, IL-6 and ICAM-1
(Figure 5B), this effect was more pronounced, both in LP1 and
RPMI8226 cells, when anti-IGF-1R antibody was combined with
AS602868.
Finally, we studied by RT-PCR the level of IGF-1.
Interestingly, we found that the combination suppressed the
level of IGF-1 whereas anti-IGF-1R or AS602868 alone did not
have any effect on IGF-1 mRNA content in these cells
(Figure 5B). Level expression of IGF-1 protein was detected also
by western blot. The level expression of protein IGF-1 decreases
in cell exposed to the combination anti-IGF-1R and AS602868
(Figure S3).
Effect of AS602868 and anti-IGF-1R antibody on PI-3K/Akt
pathways
Since IGF-1 is involved in the activation of PI-3K/Akt
pathways, we analysed the effect of its inhibition on the
RPMI8226 cell line. We observed that the phosphorylation of
Akt decreased in cells exposed to anti-IGF-1R. This inhibition of
Akt phosphorylation causes a subsequent inhibition of the
phosphorylation of the mTor pathway proteins, p70S6K and
4EBP1 (Figure 6A).
Effect of AS602868 and anti-IGF-1R antibody on Bcl-2
family proteins
As anti-IGF-1R-induced apoptosis of MM cell lines was not
associated with depolarization of the mitochondrial membrane,
we sought to determine whether alteration in IGF-1 signalling
could alter the content of pro-apoptotic and anti-apoptotic
proteins. We observed that anti- IGF-1R antibody increased the
content of pro-apoptotic proteins Bim and Bad and decreased
those of anti-apoptotic proteins Bcl-2 and Bcl-xL (Figure 6B).
AS602868 did not affect the content of these proteins under these
conditions.
Figure 3. AS602868 and anti-IGF-1R antibody block the cell cycle in RPMI8226 and LP cell lines. 3.A Effect of AS602868 and anti-IGF-1R
antibody on the cell cycle. MM cell lines were exposed for 40 h to 10 mM AS602868 or/and 10 mg/mL anti-IGF-1R antibody at 37uC. Cells were
incubated with propidium iodide and then analyzed with flow cytometry. 3.B Analysis of cell cycle proteins in RPMI8226 cells exposed to AS602868
or/and anti- IGF-1R. RPMI8226 cells were incubated with 10 mM AS602868 or/and anti-IGF-1R antibody 10 mg/mL for 16 h then examined by Western
blotting. Mean6 SD of three experiments ** P,0.001: * P,0.05 versus control.
doi:10.1371/journal.pone.0022641.g003
Anti-IGF-1R Potentiate the Effect of AS602868
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Despite the fact that several treatments for multiple myeloma
are currently available, the median survival of multiple myeloma
remains in the order of 5 years, in particular in patients who are
not eligible for high dose therapy. Many studies proved the
importance of the activation of signalling pathways in chemo-
resistance, cell survival, and proliferation of human multiple cells
lines [30]. This makes these signalling pathways a therapeutic
target in multiple myeloma. Over the past few years, several
studies have shown that inhibition of these signalling pathways by
specific inhibitors or by blocking the activator of these pathways
causes an inhibition of cell proliferation [31,32]. The prolifer-
ation and the survival of MM cells are strongly dependent on the
activation of signalization pathways by cytokines and growth
factors [33,34,35]. Most of these cytokines and growth factors are
secreted by the microenvironment, in particular the bone
marrow stromal cells [36,37]. IGF-1 is now considered as a
m a j o rg r o w t hf a c t o ri nM M[ 3 8 ] .P r e v i o u ss t u d i e si d e n t i f i e da
role of IGF-1 as a growth and survival factor in MM. In vivo and
in vitro studies proved IGF-1 increase antiapoptotic proteins (such
as Bcl-2, Bcl-XL, cIAP-1, cIAP-2, FLIP) and decrease pro
apoptotic proteins (such as caspase 3, caspase 8, caspase 9) and
plays a role in drug resistance (dexamethasone, rapamy-
cine)[39,40,41] Many studies in multiple myeloma have shown
that the role of IGF-1 is correlated with signalling pathway
activation. IGF-1 plays a major role in NF-kB, PI-3K/Akt and
ras/MaPK activation [12,30,42].The inhibition of the interac-
tion between IGF-1 and its receptor is being explored as a
therapeutic target in this disease [43,44,45,46]. In vitro and in vivo
studies have proved that the inhibition of of IGF-1R decreased
cell proliferation [16,44,47]. Our results confirm the wide-
ranging effect of IGF-1 inhibition on myeloma cells, including
blockage of the G1 to S phase, reduced PI3K signalling and
altered equilibrium of pro- and anti-apoptotic proteins. We show
that the cytotoxic effect of anti-IGF-1R is more important on
MM cell lines with a high level of IGF- 1R. In primary MM cell
lines, anti-IGF-1R antibody enhanced the apoptotic effect of the
IKK2 inhibitor AS602868 only in plasma cells with high
expression of IGF-1R. Constitutive nuclear NF-kBa c t i v i t yh a s
been described in many MM cells lines and primary myeloma
cells [48]. Spontaneous and abnormal activation of NF-kBh a s
Figure 4. AS602868 induces the depolarization of mitochondrial membrane. 4.A AS602868 and anti-IGF-1R antibody increased the
depolarization of mitochondrial membrane in RPMI8226 and LP1 cell lines. Cells were incubated with 10 mM AS602868 or/and anti-IGF-1R antibody
10 mg/mL for 16 h then analysed by flow cytometry. 4.B AS602868 increased the level expression of cytochrome c in RPMI8226 and LP1 cell lines.
Cells were incubated with 10 mM AS602868 or/and anti-IGF-1R antibody 10 mg/mL for 16 h.
doi:10.1371/journal.pone.0022641.g004
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22641Figure 5. AS602868+anti-IGF-1R antibody inhibit the NF-kB pathway in RPMI8226 and LP1 cells. 5.A AS602868 and anti-IGF-1R antibody
decreased the level of NF-kB proteins pathways. RPMI8226 cells were treated for 16 h with 10 mg/mL anti-IGF-1R antibody or/and 10 mM AS602868 at
37uC. 5.B AS602868 and anti-IGF-1R antibody inhibited the expression of NF-kB regulated genes in multiple myeloma (IKB, IGF1, IL-6 and ICAM-1).
Mean6 SD of three experiments ** P,0.001: * P,0.05 versus control.
doi:10.1371/journal.pone.0022641.g005
Figure 6. Effect of AS602868 and anti-IGF-1R antibody on PI-3K/Akt pathway and proand anti-apoptotic proteins in RPMI8226 and
LP1 cell lines. 6.A Anti-IGF-1R antibody inhibits the phosphorylation of Akt, p70S6K and 4EBP-1 in RPMI8226. 6.B Anti-IGF-1R antibody induces the
expression of pro-apoptotic proteins. Cells were incubated for 16 h with 10 mg/mL anti-IGF-1R antibody or/and 10 mM AS602868.
doi:10.1371/journal.pone.0022641.g006
Anti-IGF-1R Potentiate the Effect of AS602868
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confirming the importance of inhibing NF-kB as a therapeutic
target in MM [5]. MM cells have been shown to be sensitive to
NF-kB inhibitors including proteasome inhibitors and IKK
inhibitors [22,49,50]. Preclinical and clinical studies have shown
that the IKK2 inhibitors AS602868 and TPCA-1 induce
apoptosis in MM cells by decreasing the canonical NF-kB
pathway [27]. In our study, we observed the effect of the
combination of monoclonal anti-IGF-1R antibody and IKK2
inhibitors. Interestingly, among the four cell lines with different
expression levels of IGF-1R which we studied, only in those with
the highest levels did we observe enhanced cytotoxic activity of
IKK2 inhibitors by anti-IGF-1R antibody. We observed that the
apoptotic response of MM cells to AS602868 involved disruption
of the mitochondrial transmembrane potential and release of
cytochrome c. While anti-IGF-1R antibody did not induce
mitochondrial membrane depolymerisation it did alter the
expression levels of pro- and anti-apoptotic proteins, possibly
through inhibition of PI3K signalling, a factor which might
explain why the combination with AS602868 resulted in greater
cytochrome c content than that caused by AS602868 alone.
Moreover, inhibition of IGF-1 signalling by the anti-IGF-1R
antibody, while in itself did not reduce NF-kB signalling, resulted
in decreased phospho-IkB, thereby setting the stage for the effect
of AS602868 on NF-kB signalling. The inhibition of NF-kB was
associated with a reduction in the expression of adhesion molecule
ICAM-1 and IL-6. In this study, we show that the combination of
two pathways inhibitors decreased the production of IGF-1 and
IL-6. Altogether, our data underscore the central role for IGF-1 in
MM and the importance of IGF-1 signalling as a potential
therapeutic target. Interestingly our results suggest that inhibition
of IGF-1 signalling in MM could be used as a chemosensitization
strategy rather than as a cytotoxic approach per se. We indeed
observed that exposure to anti-IGF-1R antibody contributed to
mitochondrial membrane disruption and NF-kB inhibition caused
by the IKK inhibitor AS602868. These results were all the more
remarkable as these two agents had different effects on the cell
cycle and that the combination of the two had an effect super
imposable to that of the anti-IGF-1R antibody. These findings
suggest that a strategy combining monoclonal antibody against
IGF-1R with NF-kB inhibitors may constitute a promising
therapeutic approach in patients with MM.
Materials and Methods
Cell lines
Human multiple myeloma cell lines LP1, RPMI8226, U266 and
MM.1S were cultured in RPMI 1640 containing L-Glutamine
(Invitrogen, Cergy Pontoise, France), 10% fetal bovine serum
(Invitrogen, Cergy Pontoise, France) and 1% penicillin strepto-
mycin (Invitrogen, Cergy Pontoise, France) at 37uC in humidified
95% air and 5% CO2. LP1, MM.1S and U266 were provided by
ATCC-LGC (Molsheim, France). RPMI8226 was provided by
ECACC from sigma-Aldrich (Sigma Aldrich, St Louis, USA).
Growth inhibition Assay
The cell survival was assessed by using a 3-(4,5-dimethylthiazol-
2-yl)-2,5- diphenyltetrazolium bromide assay (MTT, Sigma
Aldrich, St Louis, USA). Cells were cultured in 96-well plates
(Costar, NY, USA) for 72 h in the presence of AS602868
(generously provided by Merck-Serono, Geneva, Switzerland),
TPCA-1(Sigma Aldrich, St Louis, USA) alone or with an anti-
IGF-1Rmonoclonal antibody (generously provided by Roche,
Penzberg, Germany). Cells were then incubated with 100 mg
MTT, and the resulting crystals were resuspended in 100 mLo f
isopropanol/0.1 N HCl (Sigma Aldrich, St Louis, USA). Absor-
bance was measured at 540–690 nm using a spectrophotometer
(Thermo Electron Corporation), and inhibitory concentrations 50
(IC50) were determined from cell survival curves drawn with Excel
(Microsoft).
Fresh human myeloma cell studies
We received 2 mL samples of bone marrow (BM) from patients
with multiple myeloma, after having obtained written informed
consent. Samples were lysed with lysis buffer for 10 minutes at
room temperature. BM cells were washed and suspended in 300 ml
phosphate buffer (PBS). Cells were cultured in 24 well plates
(Costar, NY, USA) at 37uC with AS602868 (10 mM), anti-IGF-1R
(10 mg/mL) or AS602868+anti-IGF-1R. After 24 h, cells were
washed with PBS for 5 minutes, centrifuged at 600 g at room
temperature and incubated with labelled monoclonal antibodies
directed against CD 38, CD 138, CD221(IGF-1R alpha) and
CD45 (antibodies Reference in Table S2) for 15 minutes in the
dark at room temperature. Cells were washed with PBS and
suspended in 100 mL Annexin buffer with 1 ml Annexin-V FITC
and analysed by flow cytometry on a FACS Canto II (BD
Biosciences, Erembodegem, Belgium).
Western blot analysis
Cells (1.107) were exposed to 10 mM AS602868 or/and 10 mg/
mL anti-IGF-1R for 16 hours. Following treatment, cells were
washed with phosphate-buffered saline (PBS) and then solubilised
for 30 minutes on ice in lysis buffer (20 mmol/L Tris-Hcl
(pH 6.8), 1 mmol/L MgCl2, 2 mmol/L EGTA, 0.5% NP40)
with the complete mixture of protease inhibitors (leupeptin,
aprotinin, benzamidine, PMSF, TRCK). After incubation, cell
debris and nuclei were removed by centrifugation at 12,000 g for
15 minutes at 4uC. Equal amounts of total protein (50 mg per lane)
combined with Laemmli buffer were boiled at 95uC for 5 minutes,
and then separated on 12% sodium dodecyl sulphate (SDS)-
polycrylamide gels followed by electrophoretic transfer to iBlot Gel
transfer stacks PVDF or nitrocellulose (Invitrogen). Membranes
were blocked for 1 hour at room temperature with phosphate-
buffered saline containing 0.1% TweenH 20 (PBS-T) and 5% dried
milk and incubated for all night at 4uC with specific antibody
diluted with PBS-T and 5% non fat milk. The antibodies used
were directed against Bcl-2 (M0887, 1/500, Dako, Denmark), Bcl-
XL (sc-634,1/500, Santa cruz, USA), IGF-1 (sc-1422, 1/500,
Santa cruz, USA), P21(sc-397, 1/500, Santa cruz, USA), P53
(clone DO7, 1/1000, Dako, Denmark), IkBa(ser32/ser36, IMG-
156,1/500 IMGENEX, USA), Bim (2819), Bad (610392, 1/250,
BD transduction, USA), IKKb (2684), IKKb (2681), phospho-
IKBa (S32/S36) (9426), NF-kB p65 (C22B4), phospho-NF-kB p65
(Ser536), 4EBP 1(9644), Phospho 4EBP-1(2855), p70S6k (2708),
phospho p70S6k (9209), cyclin E (4129), cyclin A (4656) (1/1000
or 1/2000, Cell Signalling, USA), Akt (IMG-5411-1, 1/250,
Imgenex, USA), phospho Akt (IMG-187-A, 1/500, Imgenex,
USA)). Membranes were washed with PBS-T 5% dried milk and
incubated with a secondary antibody against mice or rabbit
immunoglobulin (1/3000, Caltag, USA) for 1 h. Signal was
detected by chemoluminescence using ECL western blotting
detection system (GE Healthcare, UK). b- actin clone AC-15
(Sigma Aldrich, St Louis, USA) served as internal control for equal
loading.
Cell cycle analysis
Cellular DNA content was determined by flow cytometry.
After incubation with 10 mg/mL anti-IGF-1R and/or 10 mM
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with PBS and suspended in 800 mL of propidium iodide solution
(0.05 mg/mL) in the dark for 1 h at 4uC. Cells were acquired by
flow cytometry and cell cycle distribution was determined using
Modfit LT 2.0
TM software (Veritysoftware Inc, Topsham, USA).
Real-time quantitative RT-PCR
Total RNA was converted to cDNA using the Superscript II
reverse transcriptase (Invitrogen, Cergy Pontoise, France). Real-
time quantitative RT-PCR was performed using SYBR-Green
technology in a Lightcycler (Roche, Mannheim, Germany) as
previously described [29]. Forward and reverse primer sequences
used are detailed in Table S1. Results were analyzed with
RelQuant software (Roche).
Mitochondrial membrane depolarization
Cells were incubated in the presence or absence of AS602868
or/and anti-IGF-1R antibody for 16 h, washed with phosphate-
buffered saline (PBS), and incubated for 15 min at 37uC with
50 nM 3,3 dihexyloxacarbocyanine (DIOC6(3)) (Sigma Aldrich, St
Louis, USA). Cells were then washed with and resuspended in
PBS. DIOC6(3) fluorescence was measured by flow cytometry.
Apoptosis assay
Cells (1.106) were cultured at 37uC with 10 mM AS602868 or/
and 10 mM TPCA-1 or/and anti- IGF-1R antibody (10 mg/mL).
After 48 h, cells were washed with PBS 16 and suspended in
100 mL Annexin buffer with 1 ml Annexin-V FITC (Roche,
Germany). After 15 minute incubation at room temperature in the
dark, cells were washed and analyzed by flow cytometry (BD
Biosciences, Europe, Erembodegem, Belgium). The Annexin-V
FITC positive population was considered as the apoptotic fraction
in our experiments.
Statistical analysis
Statistical comparisons were made with the Student t-test. The
minimal level of significance was p,0.05.
Supporting Information
Figure S1 Cytotoxicity of anti-IGF-1R antibody in four
MM cell lines. Cells were plated in triplicate and exposed to
various concentrations of anti-IGF-1R antibody and analyzed
using an MTT assay.
(TIF)
Figure S2 Cytotoxicity assays in the absence of serum.
Cells were plated in triplicate and exposed to various concentra-
tions of AS602868 and/or anti- IGF 1R antibody 10 mg/mL.
(TIF)
Figure S3 Western blot of IGF-1 protein. RPMI8226 cells
were incubated for 16 h with 10 mg/mL anti-IGF-1R antibody
or/and 10 mM. AS602868 at 37uC.
(TIF)
Table S1 Forward and reverse primer sequences.
(XLSX)
Table S2 Antibodies reference.
(XLSX)
Table S3 Percentage of plasma cells CD221+ and
CD2212.
(XLSX)
Table S4 Effect of AS602868 and anti-IGF-1R on bone
marrow non plasma cell compartment.
(XLSX)
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